Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial.
Saved in:
| Title: | Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial. |
|---|---|
| Authors: | O'Brien TJ; Department of Neuroscience, Central Clinical School, Alfred Health, Monash University, Melbourne, Victoria, Australia.; Departments of Medicine and Neurology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia., Borghs S; UCB Pharma, Slough, UK., He QJ; UCB Pharma, Raleigh, North Carolina., Schulz AL; UCB Pharma, Monheim am Rhein, Germany., Yates S; UCB Pharma, Raleigh, North Carolina., Biton V; Clinical Trials Inc, Little Rock, Arkansas. |
| Source: | Epilepsia [Epilepsia] 2020 Apr; Vol. 61 (4), pp. 636-646. Date of Electronic Publication: 2020 Mar 28. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Blackwell Science Country of Publication: United States NLM ID: 2983306R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-1167 (Electronic) Linking ISSN: 00139580 NLM ISO Abbreviation: Epilepsia Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1528-1167 |
|---|---|
| DOI: | 10.1111/epi.16484 |
